Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997348 | 0.80 | LMNA (0.48) | LMNASMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL24322557 | 0.79 | ALDH1A1 (0.64) | LMNAALDH1A1KMT2A | |
| SCHEMBL26673580 | 0.79 | ALDH1A1 (0.49) | LMNASMN1; SMN2ALDH1A1PKMHPGD | |
| SCHEMBL8288240 | 0.78 | DPP4 (0.55) | LMNASMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL4806165 | 0.77 | LMNA (1.00) | LMNASMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL24322955 | 0.75 | ALDH1A1 (0.49) | LMNASMN1; SMN2ALDH1A1HTTKDM4E | |
| SCHEMBL25059352 | 0.75 | TDO2 (0.56) | LMNASMN1; SMN2NPC1ALDH1A1GAA | |
| SCHEMBL6267145 | 0.74 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL17346 | 0.74 | L3MBTL1 (0.51) | LMNAALDH1A1PKML3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL27032925 | 0.73 | KDM4E (0.59) | LMNAALDH1A1HPGDMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | LMNA 1889/4885SMN1; SMN2 4226/4885NPC1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.